Efficacy vs. effectiveness - Docetaxel and prednisone in hormone refractory prostate cancer

Journal of Oncology Pharmacy Practice

Volumn 14, Issue 1, 2008, Pages 45-49

  Howard, Diana N ^a   Chambers, Carole ^a   Cusano, Frances ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Docetaxel; Effectiveness; Prostate cancer

Indexed keywords

DOCETAXEL; PREDNISONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ADULT; AGED; ARTICLE; CANADA; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ALBERTA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 42949155372     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155207085387     Document Type: Article

References (9)

1. Prostate Cancer Stats: Canadian Cancer Society; [2007 April 11; cited 2007 May 24]. Available from: http://www.cancer.ca/ccs/internet/standard/ 0,2283,3172_14471_langId-en,00.html
2. Cancer Management Guidelines. Prostate: BC Cancer Agency; [2006 June; cited 2007 May 30]. Available from: http://www.bccancer.bc.ca/HPI/ CancerManagementGuidelines/Genitourinary/Prostate/Management/default.htm
3. Loblaw DA, Virgo KS, Nam R. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent or progressive prostate cancer: 2006 update of an american society of clinical oncology practice guideline. J Clin Oncol 2007; 25: 1596-605.
4. Berry W., Dakhil S., Modiano M., Gregurich M., Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168: 2439-43.
5. Kantoff PW, Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-13.
6. Tannock IF, Osoba D., Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
7. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refactory prostate cancer. N Engl J Med 2004; 351: 1513-20.
8. Tannock IF, de Wit R., Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
9. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.